ASK1 Inhibitor Compounds for Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in effectively addressing ASK1-mediated conditions such as autoimmune disorders, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases, as they fail to adequately inhibit the ASK1 signaling pathway, which plays a crucial role in these conditions.
Innovation Solution
Development of novel compounds, specifically those of Formula (I), which act as ASK1 inhibitors, capable of treating a wide range of diseases including autoimmune disorders, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases by inhibiting the ASK1 signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used, then treatment is provided for various diseases, but they fail to adequately inhibit the ASK1 signaling pathway
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of ASK1 inhibitor compounds through systematic variation of R1, R2, R3, R4, R5, and R6 substituents. This allows optimization of binding affinity and inhibitory potency against ASK1 while maintaining broad therapeutic applicability across multiple disease types including autoimmune disorders, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases
2Reliability
If ASK1 inhibition is enhanced to improve therapeutic efficacy, then treatment outcomes improve, but compound complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying substituent parameters (R1-R6) on the core chemical structure to optimize therapeutic efficacy. This allows enhancement of ASK1 inhibition potency and therapeutic benefit while maintaining reasonable structural complexity through controlled modification of specific positional substituents rather than complete structural redesign
Solution Approach 2:
The patent achieves universality by developing a core compound structure that can treat multiple disease types (autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases) through a single mechanism of ASK1 inhibition. This multi-functional approach allows one compound class to address diverse pathological conditions without requiring completely different molecular structures for each disease type
Data Source
AI summary
The present invention relates to compounds of Formula (I):Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.